Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

1. Rheumatoid Arthritis.

Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease characterized by painful, swollen joints that can severely impair physical function and quality of life. The presenting symptoms of musculoskeletal pain, swelling, and stiffness are common in clinical practice, so familiarity with diagnosing and managing RA is crucial. Patients with RA are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer

Annals of Internal Medicine2019

2. Rheumatoid Arthritis.

Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease characterized by painful, swollen joints that can severely impair physical function and quality of life. The presenting symptoms of musculoskeletal pain, swelling, and stiffness are common in clinical practice, so familiarity with diagnosing and managing RA is crucial. Patients with RA are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer

Annals of Internal Medicine2019

3. Rheumatoid Arthritis.

Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease characterized by painful, swollen joints that can severely impair physical function and quality of life. The presenting symptoms of musculoskeletal pain, swelling, and stiffness are common in clinical practice, so familiarity with diagnosing and managing RA is crucial. Patients with RA are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer

Annals of Internal Medicine2019

4. Rheumatoid Arthritis.

Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease characterized by painful, swollen joints that can severely impair physical function and quality of life. The presenting symptoms of musculoskeletal pain, swelling, and stiffness are common in clinical practice, so familiarity with diagnosing and managing RA is crucial. Patients with RA are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer

Annals of Internal Medicine2019

5. Rheumatoid Arthritis.

Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease characterized by painful, swollen joints that can severely impair physical function and quality of life. The presenting symptoms of musculoskeletal pain, swelling, and stiffness are common in clinical practice, so familiarity with diagnosing and managing RA is crucial. Patients with RA are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer

Annals of Internal Medicine2019

6. Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate

Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate Signal - Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate Dissemination Centre Discover Portal NIHR DC Discover Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate Published on 24 January 2018 It seems safer to reduce the dose of biological drugs, rather than to stop them if people with rheumatoid arthritis and their doctors want to avoid (...) relapse. Stopping these powerful drugs caused the disease to recur in 58% of people compared with 29% who continued them. Reducing the dose also led to more relapses for people in remission, but did not cause those with low-grade disease activity to worsen. Rheumatoid arthritis is a chronic disease which causes pain, swelling and stiffness in the small joints of the hands and feet. It can cause more widespread inflammation. The disease has episodes of improvement and deterioration so judging

NIHR Dissemination Centre2018

7. Existing drugs for rheumatoid arthritis may also improve associated fatigue

Existing drugs for rheumatoid arthritis may also improve associated fatigue Signal - Existing drugs for rheumatoid arthritis may also improve associated fatigue Dissemination Centre Discover Portal NIHR DC Discover Existing drugs for rheumatoid arthritis may also improve associated fatigue Published on 23 August 2016 Biological treatments for moderate to severe rheumatoid arthritis appear to reduce fatigue as well as other symptoms. Although existing studies looking at effectiveness have (...) reduction in fatigue, which may be an important consideration for patients and prescribers. Share your views on the research. Why was this study needed? Rheumatoid arthritis affects around 400,000 people in the UK. It is an autoimmune disease in which the person’s own immune system attacks their body, in this case mainly the joints, causing inflammation, swelling, stiffness, pain and irreversible joint damage. There is no cure for rheumatoid arthritis. Treatments such as anti-inflammatory painkillers

NIHR Dissemination Centre2018

8. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews

Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Uncertainty remains over the optimal prediction model(s) for early rheumatoid arthritis and there was insufficient evidence that the effect of treatment depended on baseline characteristics. {{author}} {{($index , , , , , , , & . Rachel Archer , * , Emma Hock , Jean Hamilton , John Stevens , Munira Essat , Edith Poku , Mark Clowes , Abdullah Pandor , Matt Stevenson School of Health and Related Research (ScHARR

NIHR HTA programme2018

9. Is dry heat treatment (fluidotherapy) effective in improving hand function in patients with rheumatoid arthritis? A randomized controlled trial

Is dry heat treatment (fluidotherapy) effective in improving hand function in patients with rheumatoid arthritis? A randomized controlled trial 30450972 2018 11 19 1477-0873 2018 Nov 18 Clinical rehabilitation Clin Rehabil Is dry heat treatment (fluidotherapy) effective in improving hand function in patients with rheumatoid arthritis? A randomized controlled trial. 269215518810778 10.1177/0269215518810778 To evaluate the efficacy of dry heat treatment (fluidotherapy) in improving hand function (...) in patients with rheumatoid arthritis. Prospective randomized controlled trial. Departments of Physical Medicine and Rehabilitation and Rheumatology in a university hospital. Patients with rheumatoid arthritis. All patients were randomly divided into two groups. Group 1 underwent dry heat treatment (fluidotherapy) and Group 2 was a control group. Patients in both groups participated in a joint protection and exercise program. Primary outcome measures were Health Assessment Questionnaire and Duruoz Hand

EvidenceUpdates2018

10. Sarilumab (rheumatoid arthritis) ? Benefit assessment according to §35a Social Code Book V

Sarilumab (rheumatoid arthritis) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sarilumab (Rheumatoide Arthritis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-39 (...) Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-39 Version 1.0 Sarilumab (rheumatoid arthritis) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded

Institute for Quality and Efficiency in Healthcare (IQWiG)2018

11. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment 30219772 2018 09 16 0315-162X 2018 Sep 15 The Journal of rheumatology J. Rheumatol. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. jrheum.171361 10.3899/jrheum.171361 Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid (...) and poster by all of the authors were presented at the 2017 American College of Rheumatology/ Association of Rheumatology Health Professionals Annual Meeting, November 3-8, San Diego, California, USA: "Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis." J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University

EvidenceUpdates2018

12. Comparing the effect of eye movement desensitization and reprocessing (EMDR) with guided imagery on pain severity in patients with rheumatoid arthritis

Comparing the effect of eye movement desensitization and reprocessing (EMDR) with guided imagery on pain severity in patients with rheumatoid arthritis 30319285 2018 11 14 1178-7090 11 2018 Journal of pain research J Pain Res Comparing the effect of eye movement desensitization and reprocessing (EMDR) with guided imagery on pain severity in patients with rheumatoid arthritis. 2107-2113 10.2147/JPR.S158981 Previous studies reported the reduction of pain following (...) eye movement desensitization and reprocessing (EMDR) and guided imagery; however, the effectiveness of these modalities was not compared. The current study aimed to compare the effects of EMDR and guided imagery on pain severity in patients with rheumatoid arthritis. In this randomized controlled trial, 75 patients were selected using non-random method, and then allocated into two intervention groups and one control group. Interventions were conducted individually in six consecutive sessions for the intervention groups. The Rheumatoid

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

13. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study 30194275 2018 09 08 1468-2060 2018 Sep 07 Annals of the rheumatic diseases Ann. Rheum. Dis. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. annrheumdis-2018-213271 10.1136/annrheumdis-2018-213271 This study investigated the effects of dose step-down in patients (...) with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once a day. Patients who completed a baricitinib phase 3 study could enter a long-term extension (LTE). In the LTE, patients who received baricitinib 4 mg for ≥15 months and maintained CDAI low disease activity (LDA) or remission (REM) were blindly randomised to continue 4 mg or taper to 2 mg. Patients could rescue (to 4 mg) if needed. Efficacy and safety were assessed through 48 weeks. Patients in both groups

EvidenceUpdates2018

14. Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis Is Not Superior to the ACC/AHA Risk Calculator

Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis Is Not Superior to the ACC/AHA Risk Calculator 30275258 2018 10 02 0315-162X 2018 Oct 01 The Journal of rheumatology J. Rheumatol. Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis Is Not Superior to the ACC/AHA Risk Calculator. jrheum.171008 10.3899/jrheum.171008 Cardiovascular (CV) risk estimation calculators for the general population do not perform well (...) in patients with rheumatoid arthritis (RA). An RA-specific risk calculator has been developed, but did not perform better than a risk calculator for the general population when validated in a heterogeneous multinational cohort. In a cohort of patients with new-onset RA from northern Sweden (n = 665), the risk of CV disease was estimated by the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA) and the American College of Cardiology/American Heart Association algorithm (ACC/AHA

EvidenceUpdates2018

15. Intensive therapy and remissions in rheumatoid arthritis: a systematic review

Intensive therapy and remissions in rheumatoid arthritis: a systematic review 30376836 2018 11 18 1471-2474 19 1 2018 Oct 30 BMC musculoskeletal disorders BMC Musculoskelet Disord Intensive therapy and remissions in rheumatoid arthritis: a systematic review. 389 10.1186/s12891-018-2302-5 We systematically reviewed the effectiveness of intensive treatment strategies in achieving remission in patients with both early and established Rheumatoid Arthritis (RA). A systematic literature review (...) 21360490 N Engl J Med. 2016 Mar 31;374(13):1243-52 27028914 Ann Rheum Dis. 2014 Jun;73(6):1027-36 24618266 Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S56-63 23078808 Clin Exp Rheumatol. 2013 Jul-Aug;31(4):621-32 23622099 Ann Rheum Dis. 2016 Jan;75(1):75-83 26139005 Ann Rheum Dis. 2017 Jan;76(1):96-104 27165179 Arthritis Rheum. 2012 Sep;64(9):2824-35 22508468 Early or established rheumatoid arthritis Outcome Remission Treatment response Lempp Heidi H Sturt Jackie J Prothero Louise L Neatrour Isabel

EvidenceUpdates2018

16. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. BACKGROUND: Given the phenotypic similarities between rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) (hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we hypothesized that the strongest risk factor for the development of idiopathic pulmonary fibrosis, the gain-of-function MUC5B promoter variant rs35705950, would also contribute to the risk of ILD among patients with RA. METHODS: Using

NEJM2018

17. Diagnosis and Management of Rheumatoid Arthritis: A Review.

Diagnosis and Management of Rheumatoid Arthritis: A Review. Importance: Rheumatoid arthritis (RA) occurs in about 5 per 1000 people and can lead to severe joint damage and disability. Significant progress has been made over the past 2 decades regarding understanding of disease pathophysiology, optimal outcome measures, and effective treatment strategies, including the recognition of the importance of diagnosing and treating RA early. Observations: Early diagnosis and treatment of RA can avert

JAMA2018

18. Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes

Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes 30173149 2018 09 02 0315-162X 2018 Sep 01 The Journal of rheumatology J. Rheumatol. Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes. jrheum.171375 10.3899/jrheum.171375 To investigate predictors of flare in rheumatoid arthritis (RA) patients with low disease activity (LDA) and to evaluate

EvidenceUpdates2018

19. Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study

Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study 30137547 2018 08 23 1462-0332 2018 Aug 17 Rheumatology (Oxford, England) Rheumatology (Oxford) Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study. 10.1093/rheumatology/key250 Tofacitinib is an oral Janus kinase inhibitor for treatment of RA. We compared tofacitinib modified

EvidenceUpdates2018

20. Rheumatoid arthritis

Rheumatoid arthritis Rheumatoid arthritis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Rheumatoid arthritis Last reviewed: August 2018 Last updated: September 2018 Summary A chronic, erosive arthritis that requires early and aggressive treatment. Diagnosed clinically. Laboratory and radiographic testing provide prognostic information more often than diagnostic information. Methotrexate is the anchor drug (...) for the treatment of RA. Disease activity scores (e.g., 28-joint count version of disease activity score [DAS28], clinical disease activity index [CDAI], simplified disease activity index [SDAI], routine assessment patient index data [RAPID3]) are used routinely to provide optimum care for RA patients. Definition Rheumatoid arthritis (RA) is a chronic inflammatory condition affecting around 1% of the population, making it the most common inflammatory arthritis seen by physicians. Lee DM, Weinblatt ME

BMJ Best Practice2018